Citius Oncology full-year net loss widens to $21.1M; FDA-approved LYMPHIR launch on track for H1 2025

CITIUS ONCOLOGY, INC.

Net loss $21.1M ($0.31/sh) vs $12.7M ($0.19/sh) for FY ended Sep 30, 2024.
FDA approved LYMPHIR for relapsed/refractory CTCL; commercial launch planned H1 2025.
Pre-commercial activities: J-code application, NCCN inclusion, CSO recruitment, inventory built.
R&D $4.9M, G&A $8.1M, stock-based comp $7.5M vs $4.2M, $5.9M, $2.0M YoY.
Phase I combo with pembrolizumab showed 27% ORR, 33% CBR, median PFS 57 weeks in gynecological tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.